HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase – Still a Buy?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) shares saw an uptick in trading volume on Wednesday . Approximately 32,043 shares traded hands during trading, a decline of 29% from the previous session’s volume of 45,117 shares.The stock last traded at $12.0940 and had previously closed at $11.91.

Trending Headlines about HUTCHMED

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: GSK will obtain exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830, an investigational KRAS-EGFR antibody-targeted therapy conjugate for solid tumors. HUTCHMED will receive $110 million upfront and could receive total payments of up to $1.295 billion, plus potential royalties. The drug is expected to enter clinical trials in the second half of 2026. Reuters article
• Positive Sentiment: The agreement validates HUTCHMED’s drug-discovery capabilities through a partnership with a global pharmaceutical company and provides GSK’s development and commercialization resources for HMPL-A830. The company retains rights in Greater China, preserving potential regional upside. HUTCHMED announcement
• Positive Sentiment: Daiwa Securities upgraded HUTCHMED from “Hold” to “Buy.” Panmure Liberum and Cavendish also reiterated “Buy” ratings, citing the GSK deal and what they view as an undervalued, expanding oncology pipeline. Broker reaction
• Neutral Sentiment: HUTCHMED discussed the strategic partnership and HMPL-A830 licensing terms in an investor webcast, giving shareholders additional detail on the program and collaboration. The therapy remains experimental, so future value depends on clinical-trial progress, regulatory approval and successful commercialization. Seeking Alpha transcript

Wall Street Analyst Weigh In

Several analysts have weighed in on HCM shares. Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Bank of America lowered their price objective on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Daiwa Securities Group upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Thursday. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, The Goldman Sachs Group lowered their price target on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, HUTCHMED has a consensus rating of “Hold” and an average target price of $14.87.

HUTCHMED Price Performance

The business has a 50-day moving average of $11.69 and a 200 day moving average of $12.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.09). The business had revenue of $139.14 million for the quarter, compared to the consensus estimate of $304.16 million. As a group, sell-side analysts forecast that HUTCHMED will post 0.23 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HCM. Ameriprise Financial Inc. boosted its holdings in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares during the last quarter. Bank of America Corp DE increased its stake in HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after purchasing an additional 3,035 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after buying an additional 5,538 shares during the period. Janney Montgomery Scott LLC purchased a new position in HUTCHMED during the first quarter worth about $365,000. Finally, BNP Paribas Financial Markets boosted its stake in HUTCHMED by 19.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after buying an additional 4,116 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.